(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of 6.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Maravai Lifesciences Holdings's revenue in 2026 is $204,730,000.On average, 10 Wall Street analysts forecast MRVI's revenue for 2026 to be $55,417,953,972, with the lowest MRVI revenue forecast at $52,779,249,678, and the highest MRVI revenue forecast at $57,364,708,412. On average, 10 Wall Street analysts forecast MRVI's revenue for 2027 to be $59,479,286,510, with the lowest MRVI revenue forecast at $56,019,537,241, and the highest MRVI revenue forecast at $62,515,603,780.
In 2028, MRVI is forecast to generate $63,584,511,390 in revenue, with the lowest revenue forecast at $59,156,548,705 and the highest revenue forecast at $66,881,600,806.